CDER Vs. CBER: Consulting As Usual, Or Hints Of Inter-Center Power Struggle?
This article was originally published in Pharmaceutical Approvals Monthly
In the Provenge review documents FDA has released so far, there is little indication of overt struggle between the drugs and biologics camps - but many signs that the overheated public and media atmosphere was making the agency especially careful in its dealings with the sponsor.
You may also be interested in...
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011